US FDA grants tentative approval to Liquidia's inhaled blood pressure drug
Updates shares in paragraph 1, adds background in paragraph 5
Aug 19 (Reuters) -The U.S. Food and Drug Administration on Monday delayed traditional approval for Liquidia Corp's LQDA.O drug for types of lung disorders, and allowed only tentative clearances, sending its shares plummeting nearly 37% before the bell.
The company said it has to wait for the expiration of regulatory exclusivity to United Therapeutics' UTHR.O Tyvaso DPI on May 23, 2025 before its drug can receive a final approval for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Liquidia said it will challenge the regulatory exclusivity to United's Tyvaso DPI, which encompasses chronic use of essentially any dry-powder formulation of treprostinil in both PAH and PH-ILD, granted in May 2022.
The health regulator's decision marks another setback to Liquidia's efforts to market its drug, yutrepia, which is also a dry powder formulation of treprostinil.
The drug was granted tentative approval in 2021 to treat PAH, but the company could not market it due to a regulatory stay related to a patent infringement dispute with United Therapeutics for Tyvaso.
Both Tyvaso DPI and yutrepia are delivered through a palm-sized device, making them more convenient than bulky nebulizers.
The FDA granted tentative approval yet again to yutrepia for PAH on Monday, as well as for PH-ILD, after the health regulator said it was still reviewing Liquidia's marketing application in January.
PH-ILD is a group of disorders that cause scarring in the lungs.
Reporting by Sneha S K and Sriparna Roy in Bengaluru; Editing by Tasim Zahid and Shinjini Ganguli
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
